- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00003647
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of dacarbazine with or without immunotherapy in treating patients who have stage III or stage IV melanoma.
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES: I. Demonstrate either an improvement in the median time to disease progression by at least 2 months with no decrease in the rate of objective clinical response OR an improvement by at least 15% in the rate of objective clinical response with no decrease in the median time to disease progression in patients with stage III or IV melanoma receiving dacarbazine with Allovectin-7 when compared with patients receiving dacarbazine alone.
II. Determine the benefits, risks, and side effects of these regimens in this patient population.
PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are stratified according to sex, age, and spread of disease (cutaneous or nodal vs visceral disease). Patients are randomized to one of two treatment arms.
Arm I: Patients receive dacarbazine IV over 1 hour on day 0. Arm II: Patients receive treatment as in arm I. Patients also receive Allovectin-7 intratumorally on days 3 and 10.
Patients with stable or responding disease may receive additional courses every 28 days.
Patients are followed every 4 months.
PROJECTED ACCRUAL:
A total of 280 patients (140 in each arm) will be accrued for this study.
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Bakersfield, California, United States, 93309
- Comprehensive Blood and Cancer Center
-
Encinitas, California, United States, 92023
- Scripps Memorial Hospitals-Stevens Cancer Center - Encinitas
-
San Diego, California, United States, 92120
- Kaiser Permanente-Southern California Permanente Medical Group
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520-8028
- Yale Comprehensive Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Cancer Institute
-
-
Florida
-
Miami Beach, Florida, United States, 33140
- Mount Sinai Comprehensive Cancer Center
-
Tampa, Florida, United States, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Decatur, Georgia, United States, 30033
- Georgia Cancer Specialists
-
East Point, Georgia, United States, 30344
- Georgia Cancer Specialists, P.C.
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96817
- St. Francis Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60611-3013
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
-
Park Ridge, Illinois, United States, 60068
- Lutheran General Hospital
-
-
Indiana
-
Bloomington, Indiana, United States, 47403
- Cancer Care Center for Southern Indiana
-
New Albany, Indiana, United States, 47150
- Cancer Care Center
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- Oncology and Hematology Associates
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536-0093
- Lucille Parker Markey Cancer Center, University of Kentucky
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112-2822
- Louisiana State University School of Medicine
-
-
Maryland
-
Baltimore, Maryland, United States, 21237
- Franklin Square Hospital Center
-
-
Michigan
-
Southfield, Michigan, United States, 48075
- Providence Hospital Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Virginia Piper Cancer Institute
-
Robbinsdale, Minnesota, United States, 55422
- North Memorial Health Care
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
St. Louis Park, Minnesota, United States, 55416
- Park Nicollet Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63131
- Missouri Baptist Cancer Center
-
Saint Louis, Missouri, United States, 63110-0250
- St. Louis University Health Sciences Center
-
-
Montana
-
Billings, Montana, United States, 59101
- Billings Interhospital Oncology Project
-
-
Nebraska
-
Omaha, Nebraska, United States, 68124
- Bergan Mercy Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756-0002
- Norris Cotton Cancer Center
-
-
New York
-
Brooklyn, New York, United States, 11235
- HemOnCare, P.C.
-
Great Neck, New York, United States, 11021
- Arena Oncology Associates
-
New York, New York, United States, 10003
- Beth Israel Medical Center
-
New York, New York, United States, 10029
- Mount Sinai School of Medicine
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157-1082
- Comprehensive Cancer Center at Wake Forest University
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58501
- Mid Dakota Clinic, P.C.
-
-
Ohio
-
Columbus, Ohio, United States, 43222
- Mid-Ohio Oncology/Hematology, Inc.
-
Toledo, Ohio, United States, 43623
- Toledo Clinic, Inc.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4283
- University of Pennsylvania Cancer Center
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Cancer Centers of the Carolinas
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute
-
-
Virginia
-
Danville, Virginia, United States, 24541
- Danville Hematology and Oncology, Inc.
-
Portsmouth, Virginia, United States, 23704
- Cancer Treatment Centers of America in Hampton Roads
-
-
Washington
-
Seattle, Washington, United States, 98109
- Seattle Cancer Care Alliance
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College Of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Histologically confirmed stage III or IV melanoma 1 or more metastatic tumors for which surgery is not deemed to be a curative option
- Dacarbazine is indicated as first line chemotherapy
- At least 1 measurable tumor at least 1 cm2 but no greater than 100 cm2
- No history of brain metastases
--Prior/Concurrent Therapy--
- Biologic therapy: At least 4 weeks since prior biologic therapy
- Chemotherapy: See Disease Characteristics; No prior chemotherapy
- Endocrine therapy: No concurrent immunosuppressive drugs
- Radiotherapy: At least 4 weeks since prior radiotherapy
- Surgery: At least 2 weeks since prior major surgery
- Other: No other concurrent anticancer drug therapy or experimental therapy
--Patient Characteristics--
- Age: 18 and over
- Performance status: Karnofsky 80-100%
- Life expectancy: At least 24 weeks
- Hematopoietic: WBC at least 3,000/mm3; Platelet count at least 100,000/mm3; Hemoglobin at least 9 g/dL
- Hepatic: Bilirubin no greater than 2.0 mg/dL; SGOT/SGPT less than 3 times upper limit of normal (ULN); PT/PTT normal; Albumin normal; LDH no greater than 2 times ULN
- Renal: Creatinine no greater than 2.0 mg/dL
- Cardiovascular: No uncontrolled hypertension; No New York Heart Association class III or IV disease
- Other: HIV negative; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception; No active autoimmune disease; No active infection requiring parenteral antibiotics; No uncontrolled diabetes mellitus; No other prior malignancy within the past 5 years except skin cancer or stage 0-II cervical cancer; No significant psychiatric disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Cherie Smith, Vical
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Dacarbazine
Other Study ID Numbers
- CDR0000066736
- VCL-1005-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Melanoma
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension MelanomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Uveal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension MelanomaCanada, United States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...United States, Canada, Ireland
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage III Melanoma | Extraocular Extension MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Incyte Corporation; University of VirginiaCompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma | Stage IIIA Skin Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma | Recurrent Uveal MelanomaUnited States
-
National Cancer Institute (NCI)M.D. Anderson Cancer CenterWithdrawnSorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaMelanoma | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma
-
Fred Hutchinson Cancer CenterAmazon.com Services LLCRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditionsUnited States, Canada
Clinical Trials on dacarbazine
-
Genta IncorporatedCompletedMelanomaUnited States, France, United Kingdom, Spain, Switzerland, Australia, Canada, Germany, Poland, Italy, Austria, Czech Republic
-
Cellxpert Biotechnology Corp.Medigen Biotechnology CorporationCompletedMelanomaAustralia, United States
-
Simcere Pharmaceutical Co., LtdUnknownAdvanced Melanoma | Untreated PatientsChina
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbCompleted
-
National Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
Philogen S.p.A.Eudax S.r.l.TerminatedMetastatic MelanomaSwitzerland, Italy, Austria, Germany
-
University of Erlangen-Nürnberg Medical SchoolWuerzburg University Hospital; University Hospital RegensburgRecruiting
-
Virginia Commonwealth UniversityCompletedMelanoma | Soft Tissue Sarcoma | Parathyroid Carcinoma | Small Cell Carcinoma of the Lung | Carcinoid TumorsUnited States
-
sigma-tau i.f.r. S.p.A.CompletedMalignant MelanomaFrance, Germany, Hungary, Italy, Poland, Portugal, Spain, Switzerland
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Unknown